EcoR1 Capital’s Alexion Pharmaceuticals ALXN Stock Holding History

EcoR1 Capital’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-162,200	Closed	-$19.8M	–	40
2016 Q4	$19.8M	Buy	+162,200	New	+$19.8M	6.32%	4

Other funds holding ALXN

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

EcoR1 Capital's ALXN Position: Q1 2017 in Review

EcoR1 Capital sold out of Alexion Pharmaceuticals (ALXN) in Q1 2017, closing a stake of 162,200 shares — an estimated $19.8M sold.

EcoR1 Capital first reported a position in ALXN in Q4 2016 and held it in 1 quarter. The position peaked at $19.8M in Q4 2016. 561 funds tracked by Wall St. Rank hold ALXN as of Q1 2017.

EcoR1 Capital reported no remaining Alexion Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
EcoR1 Capital sold 162,200 Alexion Pharmaceuticals shares in Q1 2017, an estimated $19.8M.
EcoR1 Capital first reported a position in Alexion Pharmaceuticals in Q4 2016 and held it in 1 quarter.
EcoR1 Capital's Alexion Pharmaceuticals position peaked at $19.8M in Q4 2016.
561 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2017.

Based on EcoR1 Capital's 13F filing for Q1 2017, filed 15 May 2017.